SCHEMBL6501193

SCHEMBL6501193

CCOC(=O)Nc1cnc(Cn2c(C)nc3ccc(C(=O)NS(=O)(=O)c4ccc(C)cc4)nc32)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
LMNA P02545 1/20 0.40
RECQL P46063 1/20 0.40
PTGS2 P35354 3/20 0.39
PTGS1 P23219 1/20 0.39
P2RY12 Q9H244 1/20 0.38
USP2 O75604 2/20 0.36
GAA P10253 1/20 0.36
ALKBH2 Q6NS38 1/20 0.35
ALKBH5 Q6P6C2 1/20 0.35
ALKBH3 Q96Q83 1/20 0.35
FTO Q9C0B1 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7065650 0.93 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HSD17B10LMNARECQL
SCHEMBL6492195 0.91 PTGS2 (0.38) ALDH1A1SMN1; SMN2PTGS2PTGS1P2RY12
SCHEMBL6493836 0.91 PTGS2 (0.38) PTGS2PTGS1USP2ALKBH2ALKBH5
SCHEMBL6490070 0.86 PTGS2 (0.44) ALDH1A1SMN1; SMN2HSD17B10PTGS2PTGS1
SCHEMBL6502274 0.86 PPARG (0.46) ALDH1A1SMN1; SMN2HSD17B10LMNAKDM4E
SCHEMBL6491410 0.85 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HSD17B10LMNAGAA
SCHEMBL6492012 0.84 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2HSD17B10LMNAGAA
SCHEMBL6502593 0.84 ALDH1A1 (0.35) ALDH1A1SMN1; SMN2HSD17B10LMNAGAA
SCHEMBL6501157 0.84 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2HSD17B10LMNAGAA
SCHEMBL7170792 0.83 RORC (0.42) ALKBH2ALKBH3FTOFLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US claimed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP claimed
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A ALDH1A1 476/4885SMN1; SMN2 325/4885HSD17B10 2591/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.